New drug shows promise for blistering skin disease in extended trial

NCT ID NCT05681481

Terminated Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who finished the main study can continue treatment for up to 48 weeks, with the option to pause and restart if symptoms return. The goal is to see if the drug is safe over time and helps control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bullous pemphigoid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BULLOUS PEMPHIGOID

Contacts and locations

Locations

Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele

Catania, 95123, Italy
Azienda Sanitaria Di Firenze

Florence, 50125, Italy
Azienda USL Toscana Centro - Ospidale Piero Palagi

Florence, 50122, Italy
Charité - Universitätsmedizin Berlin

Berlin, 10117, Germany
Diagnostic and Consulting Center Aleksandrovska EOOD

Sofia, 1431, Bulgaria
Fakultna nemocnica Trnava

Trnava, 91702, Slovakia
Fakultni nemocnice Bulovka

Prague, 180 00, Czechia
First OC Dermatology

Fountain Valley, California, 92708, United States
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

Milan, 20122, Italy
Fondazione IRCCS Policlinico San Matteo di Pavia

Pavia, 27100, Italy
Fondazione Policlinico Universitario A. Gemelli

Rome, 00168, Italy
Guy's and St Thomas' NHS Foundation Trust

London, SE1 9RT, United Kingdom
Hokkaido University Hospital

Sapporo, 060-8648, Japan
Hospital Of Skin And Venereal Diseases of Thessaloniki

Thessaloniki, 54643, Greece
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Clínico San Cecilio

Granada, 18016, Spain
Hospital Universitario Doctor Peset

Valencia, 46017, Spain
Hospital of Venereal and Skin Diseases A.Syggros

Athens, 16121, Greece
IDI IRCCS - Istituto Dermopatico dell'Immacolata

Roma, 00167, Italy
LMU Klinikum der Universität

München, 80337, Germany
Medical Dermatology Specialists

Phoenix, Arizona, 85006, United States
Miami Dermatology and Laser Institute

Miami, Florida, 33173, United States
Ospedale Policlinico San Martino

Genova, 16132, Italy
Poliklinika Solmed

Zagreb, 10000, Croatia
Premier Specialists

Kogarah, 2217, Australia
Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai, 200025, China
Saint Louis University

St Louis, Missouri, 63110, United States
Semmelweis Egyetem

Budapest, 1085, Hungary
Sheba Medical Center - PPDS

Ramat Gan, 5262100, Israel
The First Affiliated Hospital of Chongqing Medical University

Chongqing, 400016, China
Universitair Medisch Centrum Groningen

Groningen, 9713 GZ, Netherlands
Universitatsklinikum Dusseldorf

Düsseldorf, 40225, Germany
Universitatsklinikum Schleswig-Holstein

Kiel, 24105, Germany
University Clinical Center of Serbia - PPDS

Belgrade, 11000, Serbia
University of Michigan Hospital

Ann Arbor, Michigan, 48109, United States
Universitätsklinikum Carl Gustav Carus an der TU Dresden

Dresden, 01307, Germany
Universitätsklinikum Würzburg

Würzburg, 97080, Germany
Univerzitna nemocnica Bratislava

Bratislava, 821 06, Slovakia
West China Hospital of Sichuan University

Chengdu, 610041, China
Wright State Physicians

Fairborn, Ohio, 45324, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.